Physician perceptions of GLP-1 receptor agonists in the UK
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objectives Glucagon-like peptide-1 (GLP-1) receptor agonists have been used to treat type 2 diabetes for almost a decade, and new treatments in this class have recently been introduced. The purpose of this study was to examine perceptions of GLP-1 receptor agonists among physicians who treat patients with type 2 diabetes in the UK. Methods A total of 670 physicians (226 diabetes specialists; 444 general practice [GP] physicians) completed a survey in 2014. Results Almost all physicians had prescribed GLP-1 receptor agonists (95.4% total sample; 99.1% specialists; 93.5% GP), most frequently to patients whose glucose levels are not adequately controlled with oral medications (85.9% of physicians) and obese/overweight patients (83.7%). Physicians' most common reasons for prescribing a GLP-1 receptor agonist were: associated with weight loss (65.8%), good efficacy (55.7%), less hypoglycemia risk than insulin (55.2%), not associated with weight gain (34.5%), and better efficacy than oral medications (32.7%). Factors that most commonly cause hesitation when prescribing this class were: not considered first line therapy according to guidelines (56.9%), injectable administration (44.6%), cost (36.7%), gastrointestinal side effects (33.4%), and risk of pancreatitis (26.7%). Almost all specialists (99.1%) believed they had sufficient knowledge to prescribe a GLP-1 receptor agonist, compared with 76.1% of GPs. Conclusions Results highlight the widespread use of GLP-1 receptor agonists for treatment of type 2 diabetes in the UK. However, almost a quarter of GPs reported that they do not have enough knowledge to prescribe GLP-1s, suggesting a need for increased dissemination of information to targeted groups of physicians. Study limitations were that the generalizability of the clinician sample is unknown; survey questions required clinicians to select answers from multiple response options rather than generating the responses themselves; and responses to this survey conducted in 2014 do not reflect perceptions of the most recently introduced GLP-1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
Clinical Inertia Contributes to Poor Diabetes Control in a Primary Care Setting
Ziemer, D. C., Miller, C. D., Rhee, M. K., Doyle, J. P., Watkins, C., Cook, C. B., Gallina, D. L., El-Kebbi, I. M., Barnes, C. S., Dunbar, V. G., et al. (2005) · The Diabetes Educator · doi:10.1177/0145721705279050 · Cited by 208 · cited 3×
“Exenatide twice daily was the first GLP-1 receptor agonist to be approved in the UK, available since 200716.”
BackgroundMethod
Cited by
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018) · Diabetes Care · doi:10.2337/dc17-2280 · Cited by 70
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
“In a UK physician perceptions survey completed in 2014, factors that most commonly caused hesitation when prescribing GLP-1RAs included that they were not considered first-line therapy according to guidelines, their injectable mode of administration, cost, and the potential for gastrointestinal (GI) adverse effects (1…”
BackgroundHamid, A., Vaduganathan, M., Oshunbade, A. A., Ayyalasomayajula, K. K., Kalogeropoulos, A. P., Lien, L. F., Shafi, T., Hall, M. E., & Butler, J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000864 · Cited by 57
Arai, T., Atsukawa, M., Tsubota, A., Ono, H., Kawano, T., Yoshida, Y., Okubo, T., Hayama, K., Nakagawa‐Iwashita, A., Itokawa, N., et al. (2022) · JGH Open · doi:10.1002/jgh3.12780 · Cited by 34
Metadata
- Authors
- Matza, L. S., Curtis, S. E., Jordan, J. B., Adetunji, O., Martin, S. A., & Boye, K. S.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2016-02-12
- Volume
- 32
- Issue
- 5
- Pages
- 857-864
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2311442718
- Cited by
- 28
- References
- 5
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physician perceptions of GLP-1 receptor agonists in the UK. https://app.cochat.ai/papers/10.1185/03007995.2016.1147025
- The paper
- Matza, L. S., Curtis, S. E., Jordan, J. B., Adetunji, O., Martin, S. A., & Boye, K. S. (2016). Physician perceptions of GLP-1 receptor agonists in the UK. Current Medical Research and Opinion. https://doi.org/10.1185/03007995.2016.1147025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.